Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-09 11:16 am Purchase |
2022-12-30 | 13G | Denali Therapeutics Inc. DNLI |
The Vanguard Group | 9,947,098 7.320% |
1,785,568 (+21.88%) |
Filing History |
| 2023-02-09 08:14 am Sale |
2023-02-09 | 13G | Denali Therapeutics Inc. DNLI |
FMR CORP | 5,854,035 4.310% |
-737,998 (-11.20%) |
Filing History |
| 2023-01-31 5:52 pm Purchase |
2022-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BLACKROCK INC BLK |
9,321,429 6.900% |
1,210,607 (+14.93%) |
Filing History |
| 2023-01-20 10:05 am Purchase |
2022-12-30 | 13G | Denali Therapeutics Inc. DNLI |
BAILLIE GIFFORD & CO | 15,119,474 11.130% |
63,093 (+0.42%) |
Filing History |
| 2022-02-14 2:37 pm Sale |
2021-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BRATTON DOUGLAS K | 7,845,189 6.400% |
-4,503,595 (-36.47%) |
Filing History |
| 2022-02-14 2:34 pm Sale |
2021-12-31 | 13G | Denali Therapeutics Inc. DNLI |
PRICE T ROWE ASSOCIATES INC | 4,635,433 3.700% |
-1,829,393 (-28.30%) |
Filing History |
| 2022-02-09 3:43 pm Purchase |
2021-12-31 | 13G | Denali Therapeutics Inc. DNLI |
The Vanguard Group | 8,161,530 6.680% |
236,473 (+2.98%) |
Filing History |
| 2022-02-09 09:11 am Purchase |
2022-02-08 | 13G | Denali Therapeutics Inc. DNLI |
FMR CORP | 6,592,033 5.397% |
424,096 (+6.88%) |
Filing History |
| 2022-02-08 3:04 pm Sale |
2021-12-31 | 13G | Denali Therapeutics Inc. DNLI |
ARCH Venture Fund VIII L.P. | 0 0.000% |
-10,735,948 (Position Closed) |
Filing History |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BLACKROCK INC BLK |
8,110,822 6.600% |
1,734,744 (+27.21%) |
Filing History |
| 2022-01-18 11:50 am Purchase |
2021-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BAILLIE GIFFORD & CO | 15,056,381 12.330% |
2,866,125 (+23.51%) |
Filing History |
| 2021-02-16 5:08 pm Sale |
2020-12-31 | 13G | Denali Therapeutics Inc. DNLI |
Flagship Ventures Fund V, L.P. | 2,730,263 2.200% |
-5,250,000 (-65.79%) |
Filing History |
| 2021-02-16 12:24 pm Purchase |
2020-12-31 | 13G | Denali Therapeutics Inc. DNLI |
PRICE T ROWE ASSOCIATES INC | 6,464,826 5.300% |
6,464,826 (New Position) |
Filing History |
| 2021-02-12 4:19 pm Sale |
2020-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BRATTON DOUGLAS K | 12,348,784 10.300% |
-8,066,751 (-39.51%) |
Filing History |
| 2021-02-10 10:46 am Purchase |
2020-12-31 | 13G | Denali Therapeutics Inc. DNLI |
The Vanguard Group | 7,925,057 6.610% |
1,717,515 (+27.67%) |
Filing History |
| 2021-02-08 10:19 am Purchase |
2021-02-05 | 13G | Denali Therapeutics Inc. DNLI |
FMR CORP | 6,167,937 5.143% |
379,133 (+6.55%) |
Filing History |
| 2021-02-02 5:04 pm Purchase |
2020-12-31 | 13G | Denali Therapeutics Inc. DNLI |
ARCH Venture Fund VIII L.P. | 10,735,948 9.000% |
37,339 (+0.35%) |
Filing History |
| 2021-02-02 2:56 pm Purchase |
2020-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BLACKROCK INC BLK |
6,376,078 5.300% |
1,348,764 (+26.83%) |
Filing History |
| 2021-01-12 09:24 am Purchase |
2020-12-31 | 13G | Denali Therapeutics Inc. DNLI |
BAILLIE GIFFORD & CO | 12,190,256 10.170% |
4,600,009 (+60.60%) |
Filing History |
| 2020-09-28 4:11 pm Purchase |
2020-09-22 | 13G | Denali Therapeutics Inc. DNLI |
BIOGEN IDEC INC BIIB |
13,310,243 11.160% |
13,310,243 (New Position) |
Filing History |